Literature DB >> 1672642

Complementary roles for CD2 and LFA-1 adhesion pathways during T cell activation.

P E Moingeon1, J L Lucich, C C Stebbins, M A Recny, B P Wallner, S Koyasu, E L Reinherz.   

Abstract

The influence of T cell receptor (TcR) triggering on T cell adhesion function has been systematically investigated in the present studies; we show that the adhesion function of LFA-1 is minimal in non-activated T cells but is augmented within minutes following TcR-mediated activation. In contrast, CD2 function is essentially optimal in non-activated T cells and undergoes no detectable modification within 12 h of TcR stimulation. Protein kinase C activation augments LFA-1 but not CD2 adhesion function and cyclic AMP reduces LFA-1 adhesion without affecting CD2-LFA-3 interactions. Up-regulation of the LFA-1 pathway occurs in the absence of any detectable surface redistribution of this molecule, suggesting an activation dependent modification leading to a high-affinity ICAM-1 binding state. The TcR independence of CD2 adhesion function implies a critical role of the CD2 pathway in initiating cell-cell interactions prior to TcR engagement and LFA-1-ICAM-1 binding and underscores the complementary nature of the CD2 and LFA-1 adhesion pathways during the immune response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672642     DOI: 10.1002/eji.1830210311

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance.

Authors:  Elena V Tibaldi; Ravi Salgia; Ellis L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

2.  Variant antigenic peptide promotes cytotoxic T lymphocyte adhesion to target cells without cytotoxicity.

Authors:  D M Shotton; A Attaran
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Increased adherence of CD2 peripheral blood lymphocytes to cytomegalovirus-infected fibroblasts is blocked by anti-LFA-3 antibody.

Authors:  J E Grundy; G S Pahal; A N Akbar
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

4.  Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles.

Authors:  G H Guibinga; H Lochmuller; B Massie; J Nalbantoglu; G Karpati; B J Petrof
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation.

Authors:  K Yamashita; C R Parish; H S Warren; L C Harrison
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

Review 6.  Current and emerging systemic treatment strategies for psoriasis.

Authors:  Philip M Laws; Helen S Young
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 7.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

8.  A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen.

Authors:  W C Hahn; Y Rosenstein; V Calvo; S J Burakoff; B E Bierer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

Review 9.  Antibody-based therapy of leukaemia.

Authors:  John C Morris; Thomas A Waldmann
Journal:  Expert Rev Mol Med       Date:  2009-09-30       Impact factor: 5.600

Review 10.  Microchimerism, dendritic cell progenitors and transplantation tolerance.

Authors:  A W Thomson; L Lu; N Murase; A J Demetris; A S Rao; T E Starzl
Journal:  Stem Cells       Date:  1995-11       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.